Skip to main content

Table 3 Association of the expression level of molecular biomarkers with PFS/OS

From: Characterization of ovarian clear cell carcinoma using target drug-based molecular biomarkers: implications for personalized cancer therapy

Molecular biomarkers High-grade serous carcinoma Clear cell carcinoma P e value
  Cases (%) P(OS) P(PFS) Cases (%) P(OS) P(PFS)  
EGFR 113(100) 0.017 0.042 92(100) 0.012 0.267 0.195
 Negative 82(72.6)    59(64.1)    
 Positive 31(27.4)    33(35.9)    
HER2 113(100) 0.938 0.475 95(100) 0.001 0.200 0.006
 Negative 110(97.3)    83(87.4)    
 Positive 3(2.7)    12(12.6)    
PTEN 113(100) 0.323 0.397 93(100) 0.160 0.061 0.716
 Negative 99(87.6)    83(89.2)    
 Positive 14(12.4)    10(10.8)    
AURKA 113(100) 0.006 0.382 95(100) 0.022 0.035 0.582
 Negative 72(63.7)    57(60.0)    
 Positive 41(36.3)    38(40.0)    
BRCA1 113(100) 0.017 0.032 92(100) 0.823 0.424 0.007
 Negative 82(72.6)    50(54.3)    
 Positive 31(27.4)    42(45.7)    
BRCA2 113(100) 0.743 0.500 94(100) 0.466 0.929 0.054
 Negative 101(89.4)    75(79.8)    
 Positive 12(10.6)    19(20.2)    
PD-L1 113(100) 0.037 0.159 95(100) 0.773 0.425 0.064
 Negative 99(88.4)    75(78.9)    
 Positive 13(11.6)    20 (21.1)    
  1. A total of 113 cases of HGSC and 96 cases of CCC have both primary tumor immunohistochemistry results and survival information. However, the total number for each antibody does not add to up 96 in CCC group
  2. aChi-squared tests were performed for the difference of positive rates between HGSC and CCC groups
  3. Bold value denotes P with statistical significance